Welcome,
and thank you for visiting the official website of GEM Biosciences.

Founded in 2017 by a team of researchers from Asan Medical Center in Seoul, GEM Biosciences is a biotechnology company dedicated to advancing preclinical research through the development and localization of next-generation genetically engineered animal models.

Since our inception, we have focused on addressing a critical gap in Korea’s biomedical research infrastructure — the full reliance on imported severely immunodeficient mice. Utilizing cutting-edge gene-editing technologies such as the third-generation CRISPR system (Cpf1), we successfully developed knockout models targeting prkdc, il2rg, and rag2 genes. This led to the domestic production of advanced strains including NSG and NRG mice, significantly enhancing the accessibility and reliability of preclinical models for Korean researchers and pharmaceutical developers.

In 2020, we achieved another milestone by becoming the first company in Korea to successfully produce and commercialize humanized mice. These models, engrafted with human hematopoietic stem cells, have become essential tools in evaluating the efficacy of immunotherapies and biologics. We are currently working toward the full localization of humanized mice production and preparing for entry into the global market.

At GEM Biosciences, we go beyond animal model production. Our services encompass the development of disease-specific models, immune profiling, and contract research solutions that support integrated translational research. With our expertise and commitment, we strive to be a trusted partner in accelerating biomedical innovation.

We remain dedicated to scientific excellence, technological innovation, and advancing the global life science ecosystem.
Thank you.

CEO, GEM Biosciences